Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
PepGen Inc. - Common Stock
(NQ:
PEPG
)
11.68
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
11.68
Bid (Size)
6.200 (1)
Ask (Size)
17.99 (1)
Prev. Close
11.68
Today's Range
11.68 - 11.68
52wk Range
3.720 - 17.51
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
12 Health Care Stocks Moving In Friday's Pre-Market Session
April 12, 2024
Via
Benzinga
Insiders Buying GameStop And 2 Other Stocks
April 10, 2024
Although U.S. stocks closed mixed on Tuesday, there were a few notable insider trades.
Via
Benzinga
Performance
YTD
+64.74%
+64.74%
1 Month
-19.34%
-19.34%
3 Month
+61.10%
+61.10%
6 Month
+108.20%
+108.20%
1 Year
-18.15%
-18.15%
More News
Read More
PepGen to Participate in Upcoming Investor Conferences
March 13, 2024
From
PepGen Inc.
Via
GlobeNewswire
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
March 13, 2024
From
PepGen Inc.
Via
GlobeNewswire
PEPG Stock Earnings: PepGen Beats EPS for Q4 2023
March 06, 2024
Via
InvestorPlace
PepGen: Q3 Earnings Insights
November 08, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
March 07, 2024
Via
Benzinga
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
March 06, 2024
From
PepGen Inc.
Via
GlobeNewswire
PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
March 04, 2024
From
PepGen Inc.
Via
GlobeNewswire
PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1
February 20, 2024
From
PepGen Inc.
Via
GlobeNewswire
Over $37M Bet On This Industrial Stock? Check Out These 4 Stocks Insiders Are Buying
February 14, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
February 07, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
February 07, 2024
Via
Benzinga
PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock
February 07, 2024
From
PepGen Inc.
Via
GlobeNewswire
PepGen soars on Sarepta Therapeutics’ Duchenne drug phase 2 data
February 06, 2024
Via
MarketBeat
Top 4 Health Care Stocks That May Crash This Quarter
February 02, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
January 30, 2024
Via
Benzinga
Mary Beth DeLena Joins PepGen as General Counsel and Secretary
January 17, 2024
From
PepGen Inc.
Via
GlobeNewswire
PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping
January 08, 2024
From
PepGen Inc.
Via
GlobeNewswire
PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
December 18, 2023
From
PepGen Inc.
Via
GlobeNewswire
PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors
November 15, 2023
From
PepGen Inc.
Via
GlobeNewswire
PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
November 08, 2023
From
PepGen Inc.
Via
GlobeNewswire
PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
October 12, 2023
From
PepGen Inc.
Via
GlobeNewswire
PepGen Announces Upcoming Presentations at the 28th Annual Congress of the World Muscle Society and the World Congress of Neurology
September 27, 2023
From
PepGen Inc.
Via
GlobeNewswire
PepGen Inc. Announces Clearance of CTA by Health Canada to Begin the FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 in Patients with Myotonic Dystrophy Type 1
September 06, 2023
From
PepGen Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
